Claims for Patent: 7,799,761

Summary for Patent: 7,799,761

Title:	Pharmaceutical compositions including low dosages of desmopressin
Abstract:	The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 .mu.g desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed.
Inventor(s):	Fein; Seymour H. (New Canaan, CT)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	10/706,100
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,799,761
Patent Claims:	1. A pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier in a dosage form which dispenses by intranasal, transdermal, or intradermal administration from 0.5 ng up to 1 .mu.g desmopressin. 2. The pharmaceutical composition of claim 1 in a dosage form comprising a patch, gel, cream, ointment, or iontophore adapted for transdermal delivery. 3. The pharmaceutical composition of claim 1 in a dosage form comprising a patch adapted for intradermal administration. 4. The pharmaceutical composition of claim 1 in a dosage form comprising a spray adapted for intranasal delivery. 5. The pharmaceutical composition of claim 1 in a dosage form sufficient to establish in a patient a steady plasma/serum desmopressin concentration of from about 0.1 picograms desmopressin per mL plasma/serum to 10 picograms desmopressin per mL plasma/serum. 6. The pharmaceutical composition of claim 1 in a dosage form sufficient to establish in a patient a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picograms desmopressin per mL plasma/serum. 7. A pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier in a dosage form adapted for intranasal administration which dispenses from 0.1 ng up to 1 .mu.g desmopressin and which when administered to a patient establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about a maximum of 10.0 picograms desmopressin per mL plasma/serum and decreases urine production. 8. The composition of claim 7 which establishes a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picograms desmopressin per mL plasma/serum. 9. A pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier in a dosage form adapted for intradermal or transdermal administration which dispenses from 0.1 ng up to 1 .mu.g desmopressin and which when administered to a patient establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about a maximum of 10.0 picograms desmopressin per mL plasma/serum and decreases urine production. 10. The dosage form of claim 9 which establishes a steady plasma/serum desmopressin concentration of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picograms desmopressin per mL plasma/serum. 11. The dosage form of claim 9 adapted for intradermal administration comprising a patch. 12. The dosage form of claim 9 adapted for transdermal delivery and comprising a patch, gel, cream, ointment, or iontophore. 13. The composition of claim 1 which establishes said plasma/serum desmopressin concentration range for a time between four and six hours. 14. The composition of claim 7 which establishes said plasma/serum desmopressin concentration range for a time between four and six hours. 15. The composition of claim 8 which establishes said plasma/serum desmopressin concentration range for a time between four and six hours. 16. The composition of claim 9 which establishes said plasma/serum desmopressin concentration range for a time between four and six hours. 17. The composition of claim 10 which establishes said plasma/serum desmopressin concentration range for a time between four and six hours.